BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34740271)

  • 21. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
    Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
    BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic and prognostic role of SF1, IGF2, Ki67, p53, adiponectin, and leptin receptors in human adrenal cortical tumors.
    Babińska A; Pęksa R; Wiśniewski P; Świątkowska-Stodulska R; Sworczak K
    J Surg Oncol; 2017 Sep; 116(3):427-433. PubMed ID: 28672049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weineke criteria, Ki-67 index and p53 status to study pediatric adrenocortical tumors: Is there a correlation?
    Das S; Sengupta M; Islam N; Roy P; Datta C; Mishra PK; Banerjee S; Chaudhuri MK; Chatterjee U
    J Pediatr Surg; 2016 Nov; 51(11):1795-1800. PubMed ID: 27567308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Filamin a Expression in Adrenocortical Carcinomas Is Associated with a Favourable Tumour Behaviour: A European Multicentric Study.
    Catalano R; Altieri B; Angelousi A; Arosio M; Bravi F; Canu L; Croci GA; Detomas M; Esposito E; Ferrante E; Ferrero S; Fuss CT; Kaltsas G; Kimpel O; Landwehr LS; Luconi M; Morelli V; Nesi G; Nozza E; Sbiera S; Serban AL; Ronchi CL; Mantovani G; Peverelli E
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myxoid and Sarcomatoid Variants of Adrenocortical Carcinoma: Analysis of Rare Variants in Single Tertiary Care Center.
    Sung TY; Choi YM; Kim WG; Lee YM; Kim TY; Shong YK; Kim WB; Song DE
    J Korean Med Sci; 2017 May; 32(5):764-771. PubMed ID: 28378549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection.
    Beuschlein F; Weigel J; Saeger W; Kroiss M; Wild V; Daffara F; Libé R; Ardito A; Al Ghuzlan A; Quinkler M; Oßwald A; Ronchi CL; de Krijger R; Feelders RA; Waldmann J; Willenberg HS; Deutschbein T; Stell A; Reincke M; Papotti M; Baudin E; Tissier F; Haak HR; Loli P; Terzolo M; Allolio B; Müller HH; Fassnacht M
    J Clin Endocrinol Metab; 2015 Mar; 100(3):841-9. PubMed ID: 25559399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Nrf2 expression and mutation with Weiss and Helsinki scores in adrenocortical carcinoma.
    Kamai T; Murakami S; Arai K; Ishida K; Kijima T
    Cancer Sci; 2022 Jul; 113(7):2368-2377. PubMed ID: 35467062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma.
    Landwehr LS; Altieri B; Schreiner J; Sbiera I; Weigand I; Kroiss M; Fassnacht M; Sbiera S
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32474412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adrenocortical cancer (ACC) - literature overview and own experience.
    Dworakowska D; Drabarek A; Wenzel I; Babińska A; Świątkowska-Stodulska R; Sworczak K
    Endokrynol Pol; 2014; 65(6):492-502. PubMed ID: 25554619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Findings on Presentation and Outcome of Patients With Adrenocortical Cancer: Results From a National Cohort Study.
    Puglisi S; Calabrese A; Ferraù F; Violi MA; Laganà M; Grisanti S; Ceccato F; Scaroni C; Di Dalmazi G; Stigliano A; Altieri B; Canu L; Loli P; Pivonello R; Arvat E; Morelli V; Perotti P; Basile V; Berchialla P; Urru S; Fiori C; Porpiglia F; Berruti A; Pia A; Reimondo G; Cannavò S; Terzolo M
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2517-2525. PubMed ID: 37022947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature.
    Wanis KN; Kanthan R
    World J Surg Oncol; 2015 Mar; 13():117. PubMed ID: 25889798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical utility of 'GRAS' parameters in stage I-III adrenocortical carcinomas: long-term data from a high-volume institution.
    Liang J; Liu Z; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Wei X; Lu Y; Zhu Y
    Endocrine; 2020 Feb; 67(2):449-456. PubMed ID: 31786772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment.
    Bussey KJ; Demeure MJ
    Future Oncol; 2009 Jun; 5(5):641-55. PubMed ID: 19519204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma.
    Sbiera S; Sbiera I; Ruggiero C; Doghman-Bouguerra M; Korpershoek E; de Krijger RR; Ettaieb H; Haak H; Volante M; Papotti M; Reimondo G; Terzolo M; Luconi M; Nesi G; Mannelli M; Libé R; Ragazzon B; Assié G; Bertherat J; Altieri B; Fadda G; Rogowski-Lehmann N; Reincke M; Beuschlein F; Fassnacht M; Lalli E
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3491-3498. PubMed ID: 28911143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutrophil-Lymphocyte Ratio as a Prognostic Marker in Adrenocortical Carcinoma.
    Solak M; Kraljević I; Zibar Tomšić K; Kaštelan M; Kakarigi L; Kaštelan D;
    Endocr Res; 2021; 46(2):74-79. PubMed ID: 33416409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histopathological diagnosis and prognostic factors in adrenocortical carcinoma.
    Aiba M; Fujibayashi M
    Endocr Pathol; 2005; 16(1):13-22. PubMed ID: 16000842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
    Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL; Sbiera S; Kraus L; Wortmann S; Johanssen S; Adam P; Willenberg HS; Hahner S; Allolio B; Fassnacht M
    Endocr Relat Cancer; 2009 Sep; 16(3):907-18. PubMed ID: 19240185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PERSONALIZED CARE OF PATIENTS WITH ADRENOCORTICAL CARCINOMA: A COMPREHENSIVE APPROACH.
    Miller BS; Else T;
    Endocr Pract; 2017 Jun; 23(6):705-715. PubMed ID: 28614035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of the Chemokine Receptors CXCR4 and CXCR7 on Clinical Outcome in Adrenocortical Carcinoma.
    Chifu I; Heinze B; Fuss CT; Lang K; Kroiss M; Kircher S; Ronchi CL; Altieri B; Schirbel A; Fassnacht M; Hahner S
    Front Endocrinol (Lausanne); 2020; 11():597878. PubMed ID: 33281749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.